A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)

JY Byun, SK Park, BP Ng, YS Liu… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of
treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to …
被引用次数：2 相关文章

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)

JY Byun, SK Park, BP Ng, YS Liu… - Expert Opinion on …, 2022 - cuk.elsevierpure.com
Introduction: Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of
treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to …

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC).

JY Byun, SK Park, BP Ng, YS Liu, CR Kim… - Expert Opinion on …, 2022 - europepmc.org
Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of treatment for non-
small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to high costs. Despite …

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)

JY Byun, SK Park, BP Ng, YS Liu… - Expert opinion on …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of
treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to …

A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC)

JY Byun, SK Park, BP Ng, YS Liu… - EXPERT OPINION …, 2022 - scholarworks.bwise.kr
Introduction: Although tyrosine kinase inhibitors (TKIs) have improved the efficacy of
treatment for non-small cell lung cancer (NSCLC), the accessibility of TKIs is limited due to …